{"filing":{"accession_number":"0001404644-26-000056","cik":"0001404644","ticker":"NGNE","company_name":"Neurogene Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"ngne-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne-20260811.htm"},"events":[{"id":26873,"run_id":24441,"accession_number":"0001404644-26-000056","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Neurogene issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 financial results including R\u0026D expenses ($25.5M), G\u0026A expenses ($11.2M), net loss ($34.5M), and cash position ($225.4M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial metrics and material clinical trial updates for the company's lead program NGN-401.","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28154,"accession_number":"0001404644-26-000056","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Neurogene issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 financial results including R\u0026D expenses ($25.5M), G\u0026A expenses ($11.2M), net loss ($34.5M), and cash position ($225.4M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial metrics and material clinical trial updates for the company's lead program NGN-401.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:33:38.976989+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28154,"accession_number":"0001404644-26-000056","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Neurogene issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 financial results including R\u0026D expenses ($25.5M), G\u0026A expenses ($11.2M), net loss ($34.5M), and cash position ($225.4M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial metrics and material clinical trial updates for the company's lead program NGN-401.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:33:38.976989+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-08-11"}]}